TSC2 and lymphangioleiomyomatosis: Moreover, knockdown of IRF7 by siRNA leads to inhibition of the growth of TSC2-deficient AML cells (Figure 6f), indicating that IRF7 may be an important therapeutic target in the treatment of LAM and other TSC-related pathologies.